Skip to main content
. 2022 Mar 26;7(6):1241–1247. doi: 10.1016/j.ekir.2022.03.020

Figure 2.

Figure 2

Use of anti–SARS-Cov-2 therapeutic antibodies between February 2021 and June 2021. The number of patients treated with bamlanivimab as monotherapy (n = 8), bamlanivimab-etesevimab (n = 39), or casirivimab-imdevimab (n = 33) is represented by month.